The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer

Research and Reports in Urology

Volumn 5, Issue , 2012, Pages 1-10

  Elkahwaji, Johny E ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Benign prostatic hyperplasia; Chronic inflammation; Inflammatory mediators; Prostate cancer

Indexed keywords

CD163 ANTIGEN; CD20 ANTIGEN; CHEMOKINE RECEPTOR CXCR5; CYCLOOXYGENASE 2; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GLUTATHIONE TRANSFERASE P1; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 8; LYMPHOTOXIN; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; AGE; B LYMPHOCYTE; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL TRANSFORMATION; CHEMICAL INJURY; CHEMOKINE RECEPTOR 5 GENE; CHRONIC DISEASE; COX 2 GENE; DENDRITIC CELL; DIET; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE; GENETIC POLYMORPHISM; GENETIC STABILITY; GENETICS; HISTOPATHOLOGY; HUMAN; IL 10 GENE; IL 1ALPHA GENE; IL 1BETA GENE; IL 8 GENE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INFLAMMATION; INFLAMMATORY CELL; LYMPHOCYTIC INFILTRATION; MACROPHAGE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PHYSICAL DISEASE; PREVALENCE; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; T LYMPHOCYTE; TNF BETA1 GENE; VESICOURETERAL REFLUX; VIRUS TRANSMISSION;

EID: 84884477915     PISSN: None     EISSN: 22532447     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. De Marzo AM, Coffey DS, Nelson WG. New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology. 1999;53(3 Suppl 3a):29-39.
2. McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care. 2006;12(Suppl 5):S122-S128.
3. Fitzpatrick JM. The natural history of benign prostatic hyperplasia. BJU Int. 2006;97(Suppl 2):3-6.
4. Fitzpatrick JM, Kirby RS. Management of acute urinary retention. BJU Int. 2006;97(Suppl 2):16-20.
5. Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res. 2008;20(Suppl 3):S11-S18.
6. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
7. Alcaraz A, Hammerer P, Tubaro A, Scroder FH, Castro R. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol. 2009;55(4): 864-873.
8. McNeal JE. Normal histology of the prostate. Am J Surg Pathol. 1988; 12(8):619-633.
9. McNeal JE. Normal anatomy of the prostate and changes in benign prostatic hypertrophy and carcinoma. Semin Ultrasound CT MR. 1988;9(5):329-334.
10. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol. 1988;12(12):897-906.
11. Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology. 2012;60(1):199-215.
12. Chughtai B, Lee R, Te A, Kaplan S. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13(3):147-150.
13. Wagenlehner FM, Elkahwaji JE, Algaba F, et al. The role of inflammation and infection in the pathogenesis of prostate carcinoma. BJU Int. 2007;100(4):733-737.
14. Omabe M, Ezeani M. Infection, inflammation and prostate carcinogenesis. Infect Genet Evol. 2011;11(6):1195-1198.
15. De Marzo AM, Nakai Y, Nelson WG. Inflammation, atrophy, and prostate carcinogenesis. Urol Oncol. 2007;25(5):398-400.
16. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7(4):256-269.
17. Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci U S A. 1995;92(12):5258-5265.
18. Giovannucci E. Medical history and etiology of prostate cancer. Epidemiol Rev. 2001;23(1):159-162.
19. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer. 2007;7(2):139-147.
20. Robert G, Salagierski M, Schalken JA, de la Taille A. Inflammation and benign prostatic hyperplasia: cause or consequence? Prog Urol. 2010;20(6):402-407.
21. Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E. Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol. 2000;37(4):404-412.
22. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl. 2010;33(3):475-488.
23. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. J Urol. 2007;178(3 Pt 1): 896-900.
24. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54(6):1379-1384.
25. Robert G, Descazeaud A, Nicolaiew N, et al. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate. 2009;69(16):1774-1780.
26. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999;155(6):1985-1992.
27. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol. 2004;172(5 Pt 2):S6-S11.
28. Palapattu GS, Sutcliffe S, Bastian PJ, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis. 2005;26(7): 1170-1181.
29. De Marzo AM, Meeker AK, Zha S, et al. Human prostate cancer precursors and pathobiology. Urology. 2003;62(5 Suppl 1):55-62.
30. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349(4):366-381.
31. De Marzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet. 2003;361(9361): 955-964.
32. Klein EA, Silverman R. Inflammation, infection, and prostate cancer. Curr Opin Urol. 2008;18(3):315-319.
33. Sutcliffe S. Sexually transmitted infections and risk of prostate cancer: review of historical and emerging hypotheses. Future Oncol. 2010;6(8): 1289-1311.
34. Pelouze PS. Gonorrhea in the Male and Female: A Book for Practitioners. Philadelphia, PA: WB Saunders; 1935.
35. Handsfield HH, Lipman TO, Harnisch JP, Tronca E, Holmes KK. Asymptomatic gonorrhea in men. Diagnosis, natural course, prevalence and significance. N Engl J Med. 1974;290(3):117-123.
36. Poletti F, Medici MC, Alinovi A, et al. Isolation of Chlamydia trachomatis from the prostatic cells in patients affected by nonacute abacterial prostatitis. J Urol. 1985;134(4):691-693.
37. Gardner WA Jr, Culberson DE, Bennett BD. Trichomonas vaginalis in the prostate gland. Arch Pathol Lab Med. 1986;110(5):430-432.
38. Thomson L. Syphilis of the prostate. Am J Syphilis. 1920;4:323-341.
39. Bushman W. Etiology of Prostatitis In: Lepor H, editor. Prostatic Diseases. Philadelphia, PA: WB Saunders; 2000:550-557.
40. Strickler HD, Goedert JJ. Sexual behavior and evidence for an infectious cause of prostate cancer. Epidemiol Rev. 2001;23(1):144-151.
41. Zambrano A, Kalantari M, Simoneau A, Jensen JL, Villarreal LP. Detection of human polyomaviruses and papillomaviruses in prostatic tissue reveals the prostate as a habitat for multiple viral infections. Prostate. 2002;53(4):263-276.
42. Samanta M, Harkins L, Klemm K, Britt WJ, Cobbs CS. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol. 2003;170(3):998-1002.
43. Kirby RS, Lowe D, Bultitude MI, Shuttleworth KE. Intra-prostatic urinary reflux: an aetiological factor in abacterial prostatitis. Br J Urol. 1982;54(6):729-731.
44. Isaacs JT. Prostatic structure and function in relation to the etiology of prostatic cancer. Prostate. 1983;4(4):351-366.
45. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440(7081):237-241.
46. Drachenberg CB, Papadimitriou JC. Prostatic corpora amylacea and crystalloids: similarities and differences on ultrastructural and histochemical studies. J Submicrosc Cytol Pathol. 1996;28(2):141-150.
47. Sugimura T, Wakabayashi K, Nakagama H, Nagao M. Heterocyclic amines: mutagens/carcinogens produced during cooking of meat and fish. Cancer Sci. 2004;95(4):290-299.
48. Knize MG, Felton JS. Formation and human risk of carcinogenic heterocyclic amines formed from natural precursors in meat. Nutr Rev. 2005;63(5):158-165.
49. Borowsky AD, Dingley KH, Ubick E, Turteltaub KW, Cardiff RD, Devere-White R. Inflammation and atrophy precede prostatic neoplasia in a PhIP-induced rat model. Neoplasia. 2006;8(9):708-715.
50. Coffey DS. Similarities of prostate and breast cancer: evolution, diet, and estrogens. Urology. 2001;57(4 Suppl 1):31-38.
51. Harkonen PL, Makela SI. Role of estrogens in development of prostate cancer. J Steroid Biochem Mol Biol. 2004;92(4):297-305.
52. Gilleran JP, Putz O, DeJong M, et al. The role of prolactin in the prostatic inflammatory response to neonatal estrogen. Endocrinology. 2003;144(5):2046-2054.
53. Huang L, Pu Y, Alam S, Birch L, Prins GS. Estrogenic regulation of signaling pathways and homeobox genes during rat prostate development. J Androl. 2004;25(3):330-337.
54. Naslund MJ, Strandberg JD, Coffey DS. The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J Urol. 1988;140(5):1049-1053.
55. Huang L, Pu Y, Alam S, Birch L, Prins GS. The role of Fgf10 signaling in branching morphogenesis and gene expression of the rat prostate gland: lobe-specific suppression by neonatal estrogens. Dev Biol. 2005; 278(2):396-414.
56. Prins GS, Birch L, Couse JF, Choi I, Katzenellenbogen B, Korach KS. Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor α: studies with αERKO and βERKO mice. Cancer Res. 2001;61(16):6089-6097.
57. Ponniah S, Arah I, Alexander RB. PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate. 2000;44(1):49-54.
58. Briganti A, Capitanio U, Suardi N, et al. Benign prostatic hyperplasia and its aetiologies. Eur Urol Suppl. 2009;8(13):865-871.
59. Abdollah F, Briganti A, Suardi N, et al. Metabolic syndrome and benign prostatic hyperplasia: evidence of a potential relationship, hypothesized etiology, and prevention. Korean J Urol. 2011;52(8):507-516.
60. Robert G, Descazeaud A, Allory Y, Vacherot F, de la Taille A. Should we investigate prostatic inflammation for the management of benign prostatic hyperplasia? Eur Urol Suppl. 2009;8(13):879-886.
61. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an inflammatory disease? Eur Urol. 2007;51(5):1202-1216.
62. Jahnisch H, Fussel S, Kiessling A, et al. Dendritic cell-based immunotherapy for prostate cancer. Clin Dev Immunol. 2010;2010:517493.
63. Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol. 2006;16(1):25-29.
64. Steiner GE, Newman ME, Paikl D, et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate. 2003;56(3):171-182.
65. Steiner GE, Stix U, Handisurya A, et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest. 2003;83(8):1131-1146.
66. Caruso C, Balistreri CR, Candore G, et al. Polymorphisms of pro-inflammatory genes and prostate cancer risk: a pharmacogenomic approach. Cancer Immunol Immunother. 2009;58(12):1919-1933.
67. Wang L, Yang JR, Yang JY, Liu ZT. Chronic inflammation in benign prostatic hyperplasia: implications for therapy. Med Hypotheses. 2008;70(5):1021-1023.
68. Penna G, Fibbi B, Amuchastegui S, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immune-mediated inflammation. J Immunol. 2009;182(7):4056-4064.
69. Descazeaud A, Weinbreck N, Robert G, et al. Transforming growth factor β-receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation. BJU Int. 2011;108(2 Pt 2):E23-E28.
70. Sutcliffe S. Sexually transmitted infections and risk of prostate cancer: review of historical and emerging hypotheses. Future Oncol. 2010;6(8): 1289-1311.
71. Sutcliffe S, Platz EA. Inflammation and prostate cancer: a focus on infections. Curr Urol Rep. 2008;9(3):243-249.
72. Vasto S, Carruba G, Candore G, Italiano E, Di Bona D, Caruso C. Inflammation and prostate cancer. Future Oncol. 2008;4(5):637-645.
73. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology. 2002;60(1):78-83.
74. Roberts RO, Bergstralh EJ, Bass SE, Lieber MM, Jacobsen SJ. Prostatitis as a risk factor for prostate cancer. Epidemiology. 2004;15(1):93-99.
75. Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL. Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J Urol. 2005;173(6):1969-1974.
76. Hayes RB, Pottern LM, Strickler H, et al. Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer. 2000;82(3):718-725.
77. Strickler HD, Goedert J. Sexual behavior and evidence for an infectious cause of prostate cancer. Epidemiol Rev. 2001;23(1):144-151.
78. Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology. 2002;13(1):72-79.
79. Taylor ML, Mainous AG 3rd, Wells BJ. Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med. 2005;37(7):506-512.
80. Rosenblatt KA, Wicklund KG, Stanford JL. Sexual factors and the risk of prostate cancer. Am J Epidemiol. 2001;153(12):1152-1158.
81. Hochreiter WW, Nadler RB, Koch AE, et al. Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions. Urology. 2000;56(6): 1025-1029.
82. Fujita K, Ewing CM, Sokoll LJ, et al. Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation. Prostate. 2008;68(8):872-882.
83. Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A. 2003;100(5): 2645-2650.
84. Culig Z, Puhr M. Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol. 2012;360(1-2):52-58.
85. Malinowska K, Neuwirt H, Cavarretta IT, et al. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer. 2009;16(1):155-169.
86. Culig Z, Steiner H, Bartsch G, Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem. 2005;95(3):497-505.
87. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer. 2004;90(12):2312-2316.
88. Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003;101(7):2620-2627.
89. Inoue K, Slaton JW, Eve BY, et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res. 2000;6(5):2104-2119.
90. Uehara H, Troncoso P, Johnston D, et al. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate. 2005;64(1):40-49.
91. Scott KA, Arnott CH, Robinson SC, et al. TNF-α regulates epithelial expression of MMP-9 and integrin αvβ6 during tumour promotion. A role for TNF-α in keratinocyte migration? Oncogene. 2004;23(41): 6954-6966.
92. Thomas GJ, Lewis MP, Hart IR, Marshall JF, Speight PM. αvβ6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int J Cancer. 2001;92(5): 641-650.
93. Park JI, Lee MG, Cho K, et al. Transforming growth factor-β1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-κB, JNK, and Ras signaling pathways. Oncogene. 2003;22(28):4314-4332.
94. Lu T, Burdelya LG, Swiatkowski SM, et al. Secreted transforming growth factor β2 activates NF-κB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci U S A. 2004; 101(18):7112-7117.
95. Lu S, Dong Z. Characterization of TGF-β-regulated interleukin-8 expression in human prostate cancer cells. Prostate. 2006;66(9): 996-1004.
96. Lu Y, Cai Z, Xiao G, Liu Y, et al. CCR2 expression correlates with prostate cancer progression. J Cell Biochem. 2007;101(3):676-685.
97. Vaday GG, Peehl DM, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate. 2006;66(2): 124-134.
98. Konig JE, Senge T, Allhoff EP, Konig W. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate. 2004;58(2):121-129.
99. Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett. 2003;191(2):125-135.
100. Fujita H, Koshida K, Keller ET, et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate. 2002;53(3):232-240.
101. Edwards J, Mukherjee R, Munro AF, Wells AC, Almushatat A, Bartlett JM. Her2 and COX2 expression in human prostate cancer. Eur J Cancer. 2004;40(1):50-55.
102. Aparicio Gallego G, Diaz Prado S, Jimenez Fonseca P, Garcia Campelo R, Cassinello Espinosa J, Anton Aparicio LM. Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer. Clin Transl Oncol. 2007;9(11):694-702.
103. Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate. 2004;61(1):60-72.
104. Risbridger GP, Bianco JJ, Ellem SJ, McPherson SJ. Oestrogens and prostate cancer. Endocr Relat Cancer. 2003;10(2):187-191.
105. Tam NN, Leav I, Ho SM. Sex hormones induce direct epithelial and inflammation-mediated oxidative/nitrosative stress that favors prostatic carcinogenesis in the noble rat. Am J Pathol. 2007;171(4): 1334-1341.
106. Harris MT, Feldberg RS, Lau KM, Lazarus NH, Cochrane DE. Expression of proinflammatory genes during estrogen-induced inflammation of the rat prostate. Prostate. 2000;44(1):19-25.
107. Prins GS, Huang L, Birch L, Pu Y. The role of estrogens in normal and abnormal development of the prostate gland. Ann N Y Acad Sci. 2006;1089:1-13.